Literature DB >> 25964170

Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.

Tingting Zhang1, Weili Yu2, Yanfei Wang3, Tao Hu4.   

Abstract

Neisseria meningitidis can cause severe and fulminant diseases such as meningitis. Meningococcal capsular polysaccharide (PS) is a key virulence determinant that is not able to induce immunological memory. Conjugation of PS to a carrier protein can significantly increase the immunogenicity of PS and induce immunological memory. Due to the classically described carrier-induced epitopic suppression (CIES) mechanisms, a strong immune response against the carrier protein could suppress the immune response to PS after coadministration of free carrier protein with the conjugate vaccine. However, it was not clear whether suppressing or enhancing the protein-specific immunogenicity could improve the PS-specific immunogenicity of the conjugate vaccine. Thus, moderate PEGylation, extensive PEGylation and oligomerization were used to regulate the immunogenicity of tetanus toxoid (TT) in the conjugate vaccine (PS-TT). Moderate PEGylation led to a 2.7-fold increase in the PS-specific IgG titers elicited by PS-TT. In contrast, extensive PEGylation and oligomerization of TT led to 1.4-fold and 1.6-fold decrease in the PS-specific IgG titers elicited by PS-TT, respectively. The PS-specific immunogenicity of PS-TT can be increased by moderate PEGylation through mild suppression of the TT-specific immunogenicity. The PS-specific immunogenicity of PS-TT was decreased through significant suppression or enhancement of the TT-specific immunogenicity. Thus, our study contributes to understand the CIES mechanisms and improve the PS-specific immunogenicity of a meningococcal PS conjugate vaccine.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Conjugate vaccine; Meningococcal polysaccharide; Oligomerization; PEGylation

Mesh:

Substances:

Year:  2015        PMID: 25964170     DOI: 10.1016/j.vaccine.2015.04.094

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity.

Authors:  Rui Yu; Junjie Xu; Tao Hu; Wei Chen
Journal:  Mediators Inflamm       Date:  2020-07-04       Impact factor: 4.711

2.  Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice.

Authors:  Essie Komla; Oscar B Torres; Rashmi Jalah; Agnieszka Sulima; Zoltan Beck; Carl R Alving; Arthur E Jacobson; Kenner C Rice; Gary R Matyas
Journal:  Vaccines (Basel)       Date:  2021-06-01

Review 3.  Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.

Authors:  Yinghan Chan; Sin Wi Ng; Sachin Kumar Singh; Monica Gulati; Gaurav Gupta; Sushil Kumar Chaudhary; Goh Bey Hing; Trudi Collet; Ronan MacLoughlin; Raimar Löbenberg; Brian G Oliver; Dinesh Kumar Chellappan; Kamal Dua
Journal:  Life Sci       Date:  2021-06-24       Impact factor: 6.780

Review 4.  Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy.

Authors:  Kyle Saylor; Frank Gillam; Taylor Lohneis; Chenming Zhang
Journal:  Front Immunol       Date:  2020-02-24       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.